


帕布昔利布鹽酸鹽作用機(jī)制 - Medchemexpress - MCE中國(guó).docx 免費(fèi)下載
版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Product Data SheetPalbociclib hydrochlorideCat. No.: HY-50767ACAS No.: 827022-32-2分式: CHClNO分量: 483.99作靶點(diǎn): CDK作通路: Cell Cycle/DNA Damage儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 5.4 mg/mL (11.16 mM; Need ultrasonic)H2O : 4.9 mg/mL (10.12 mM; Need ultrason
2、ic and warming)SolventMass1 mg 5 mg 10 mgConcentration制備儲(chǔ)備液1 mM 2.0662 mL 10.3308 mL 20.6616 mL5 mM 0.4132 mL 2.0662 mL 4.1323 mL10 mM 0.2066 mL 1.0331 mL 2.0662 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存式和期限:-80C, 6 months; -20C, 1 month。-80C 儲(chǔ)存時(shí),請(qǐng)?jiān)?6 個(gè)內(nèi)使,-20C 儲(chǔ)存時(shí),請(qǐng)?jiān)?1 個(gè)內(nèi)使。體內(nèi)實(shí)驗(yàn)請(qǐng)
3、根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?。以下溶解案都?qǐng)先按照 In Vitro 式配制澄清的儲(chǔ)備液,再依次添加助溶劑:為保證實(shí)驗(yàn)結(jié)果的可靠性,澄 的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使; 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的式助溶1. 請(qǐng)依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 0.54 mg/mL (1.12 mM); Clear solution此案可獲得 0.54 mg/mL (1.12 mM
4、,飽和度未知) 的澄清溶液。以 1 mL 作液為例,取 100 L 5.4 mg/mL 的澄 DMSO 儲(chǔ)備液加到 400 L PEG300 中,混合均勻;向上述體系中加50 L Tween-80,混合均勻;然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 0.54 mg/mL (1.12 mM); Clear solutionPage 1 of 2 www.MedChemE此案可獲得 0.54 mg/mL (1.12 mM,飽和度未知) 的澄清溶液。以 1 mL 作液為例,取
5、100 L 5.4 mg/mL 的澄 DMSO 儲(chǔ)備液加到 900 L 20% 的 SBE-CD 理鹽溶液中,混合均勻。3. 請(qǐng)依序添加每種溶劑: Lactic acid buffer (50 mM, pH 4.0)Solubility: 33.33 mg/mL (68.87 mM); Clear solution; Need ultrasonicBIOLOGICAL ACTIVITY物活性 Palbociclib hydrochloride 選擇性的 CDK4/6 抑制劑,IC50 分別為 11 nM 和 16 nM。Palbociclib hydrochloride 有潛于 ER 陽(yáng)性和
6、HER2陰性乳腺癌的研究。IC & Target Cdk4/cyclin D3 Cdk4/cyclin D1 Cdk6/cyclin D2 DYRK1A9 nM (IC50) 11 nM (IC50) 16 nM (IC50) 2000 nM (IC50)MAPK8000 nM (IC50)體外研究 The IC50 of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser780 in MDA-MB-435breast carcinoma cells is 66 nM. Pal
7、bociclib is equally effective at reducing Rb phosphorylation at Ser795 in this tumorwith an IC50 of 63 nM, and similar effects on both Ser780 and Ser795 phosphorylation are obtained in the Colo-205colon carcinoma1. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effective
8、lyinhibited by Palbociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC50s are 0.01 M, 0.01 M,0.06 M, and 0.6 M, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC5010 M).The flow cytometry results show that Palbociclib at concentrations betw
9、een 0 to 1.0 M induces G1 arrest in the AN,RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdUincorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation(indicating G1 arrest) in the AN, RY, G401 an
10、d NS cell lines, but not in the YM cell line. Palbociclib, even at aconcentration of 0.05 M, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p1 log oftumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at dosesas l
11、ow as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise,robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis isapparent at 150 mg/kg and some cell kill is evident at the highest dose1.PRO
12、TOCOLKinase Assay 1 CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cellsthrough baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792-928) of pRbfused to GST (GSTRB-Cterm). The total volume in each
13、well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 M ATP (for CDK4-cyclin D1, CDK6-cyclin D2, andCDK6-cyclin D3) or 12 M ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 Ci of -32PATP, 20 ng of enzyme,
14、1 g of GSTRB-Cterm, and Palbociclib (0.001-0.1M). All components except the -32PATPare added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the -32PATP and the plate is incubated at 25C for 15 min. The reaction is terminated by addition of 0.1 mL
15、of 20%trichloroacetic acid and the plate is kept at 4C for at least 1 hour to allow the substrate to precipitate. The wells arePage 2 of 3 www.MedChemEthen washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a plate counter.MCE has not independentl
16、y confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 MRT cell lines, G401, MP-MRT-AN (AN), KP-MRT-RY (RY), KP-MRT-NS (NS), and KP-MRT-YM (YM) cell lines areseeded in normal growth medium into 96-well cell plates. After 24 h, the culture medium is replaced with culturem
17、edium containing Palbociclib (0.05 or 1 M) or DMSO. Cells are cultured and treated in triplicate. Cell proliferationis determined 8 days after the treatment by WST-8 assay using a Cell Counting Kit-8.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Anima
18、l Mice (18-22 g) are randomized and then implanted s.c. with tumor fragments (30 mg) into the region of the rightAdministration 1 axilla. Treatment is initiated when tumors reach 100 to 150 mg. PD 0332991 (150 or 75 mg/kg, p.o.) is givenaccording to the schedule and dose indicated in the table and f
19、igure legends by gavage as a solution in sodiumlactate buffer (50 mM, pH 4.0) based on mean group body weight. In all experiments, there are 12 mice in the controlgroup and 8 mice each in the treated groups. Additional details for each experiment are given in the table legends.MCE has not independen
20、tly confirmed the accuracy of these methods. They are for reference only.戶(hù)使本產(chǎn)品發(fā)表的科研獻(xiàn) Nature. 2017 Aug 24;548(7668):471-475. Nature. 2017 Jun 15;546(7658):426-430. Cancer Cell. 2017 Apr 10;31(4):576-590.e8. Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. Mol Cell. 2020 May 7;S1097-2765(20)30269-0.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年浙江省建筑安全員《B證》考試題庫(kù)
- 《公共政策學(xué)》題庫(kù)及答案 2
- 西安信息職業(yè)大學(xué)《商業(yè)倫理》2023-2024學(xué)年第二學(xué)期期末試卷
- 2024-2025學(xué)年山東省聊城市高唐縣第二中學(xué)高三上學(xué)期12月月考?xì)v史試卷
- 武漢船舶職業(yè)技術(shù)學(xué)院《R語(yǔ)言與數(shù)據(jù)可視化》2023-2024學(xué)年第二學(xué)期期末試卷
- 湖南財(cái)經(jīng)工業(yè)職業(yè)技術(shù)學(xué)院《斜視弱視學(xué)》2023-2024學(xué)年第二學(xué)期期末試卷
- 2025青海省安全員《C證》考試題庫(kù)
- 濰坊理工學(xué)院《經(jīng)濟(jì)統(tǒng)計(jì)學(xué)》2023-2024學(xué)年第二學(xué)期期末試卷
- 臨夏現(xiàn)代職業(yè)學(xué)院《數(shù)字信號(hào)處理A》2023-2024學(xué)年第二學(xué)期期末試卷
- 平頂山學(xué)院《安全類(lèi)專(zhuān)業(yè)寫(xiě)作》2023-2024學(xué)年第二學(xué)期期末試卷
- 讀書(shū)分享課件:《一句頂一萬(wàn)句》
- 中醫(yī)藥膳專(zhuān)題講座培訓(xùn)課件
- 物業(yè)消防安全管理培訓(xùn)【共54張課件】
- 空心杯電機(jī)基礎(chǔ)知識(shí)
- DL-T+5839-2021土石壩安全監(jiān)測(cè)系統(tǒng)施工技術(shù)規(guī)范
- 歷年交管12123駕照學(xué)法減分復(fù)習(xí)題庫(kù)帶答案下載
- 人教鄂教版-科學(xué)-三年級(jí)下冊(cè)-知識(shí)點(diǎn)
- 2024-2034年中國(guó)注射用賴(lài)氨匹林行業(yè)市場(chǎng)競(jìng)爭(zhēng)格局及投資前景展望報(bào)告
- 供應(yīng)鏈可持續(xù)采購(gòu)實(shí)踐
- 菌菇智慧方艙栽培及食用菌菌包中心生產(chǎn)基地項(xiàng)目可行性研究報(bào)告
- 生物工程畢業(yè)設(shè)計(jì)開(kāi)題報(bào)告
評(píng)論
0/150
提交評(píng)論